Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
24 Julho 2023 - 9:00AM
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel treatments for patients suffering from
hematological, pulmonary and cardiovascular disorders with high
unmet medical need, today announced that Keros will host a
conference call and webcast to provide an overview of TROPOS, its
global Phase 2 clinical trial to evaluate KER-012 in combination
with background therapy in patients with pulmonary arterial
hypertension (“PAH”), on August 8, 2023 at 8:00 a.m. Eastern time.
“PAH is a debilitating disease potentially driven by imbalanced
signaling of the transforming growth factor-beta (“TGF-β”) family
of proteins, with no treatments available that halt or reverse the
disease’s progression. The predicted mechanism-of-action of
KER-012—based on preclinical and Phase 1 clinical data—suggests
that KER-012 could potentially correct dysfunctional activin
signaling in PAH without a dose-limiting red blood cell effect,”
said Dr. Mardi Gomberg-Maitland, M.D., M.Sc., Chief Clinical
Research Officer, School of Medicine Health Sciences at George
Washington University and the Director of the Pulmonary
Hypertension Program. “The TROPOS trial offers hope for improving
and potentially extending the lives of those suffering from this
devastating disease.”
“Achieving FDA clearance to initiate our Phase 2 PAH trial of
KER-012 in the United States is an important milestone for Keros,”
said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer
of Keros. “We believe this brings us one step closer to bringing a
potentially differentiated treatment option to patients living with
this disease.”
Conference Call and Webcast Information
Keros will host a conference call and webcast on August 8, 2023,
at 8:00 a.m. Eastern time, to provide an overview of the TROPOS
trial design. Joining Keros management on the call will be Dr.
Gomberg-Maitland, who serves as the TROPOS Steering Committee
Chair.
The conference call will be webcast live
at https://event.webcasts.com/starthere.jsp?ei=1626165&tp_key=42564576c9.
The live teleconference may be accessed by dialing (877) 407-0309
(domestic) or (201) 389-0853 (international). An archived version
of the call will be available in the Investors section of the Keros
website at https://ir.kerostx.com/ for 90 days following the
conclusion of the call.
About TROPOS
TROPOS is a randomized, double-blind, placebo-controlled, global
Phase 2 clinical trial to evaluate KER-012 in combination with
background therapy in patients with PAH. The primary objective of
this trial is to evaluate the effect of KER-012 on pulmonary
hemodynamics compared to placebo in participants on background PAH
therapy. The key secondary objective of this trial is to evaluate
the effect of KER-012 on exercise capacity compared to placebo on
participants on background PAH therapy.
About KER-012
KER-012 is designed to bind to and inhibit the signaling of
TGF-β ligands that stimulate smooth muscle hypertrophy and
fibrosis, including activin A, activin B and myostatin. Keros
believes that KER-012 has the potential to increase the signaling
of bone morphogenic protein (“BMP”) pathways through this
inhibition of activin A and activin B signaling, and consequently
treat diseases such as PAH that are associated with reduced BMP
signaling due to inactivating mutations in the BMP receptors.
KER-012 is being developed for the treatment of PAH and for the
treatment of cardiovascular disorders.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of novel
treatments for patients suffering from hematological, pulmonary and
cardiovascular disorders with high unmet medical need. Keros is a
leader in understanding the role of the TGF-β family of proteins,
which are master regulators of red blood cell and platelet
production as well as of the growth, repair and maintenance of a
number of tissues, including blood vessels and heart tissue. Keros’
lead protein therapeutic product candidate, KER-050, is being
developed for the treatment of low blood cell counts, or
cytopenias, including anemia and thrombocytopenia, in patients with
myelodysplastic syndromes and in patients with myelofibrosis.
Keros’ lead small molecule product candidate, KER-047, is being
developed for the treatment of functional iron deficiency. Keros’
third product candidate, KER-012, is being developed for the
treatment of PAH and for the treatment of cardiovascular
disorders.
Cautionary Note Regarding Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Words such as "believe," “hope,” “potential,”
"suggest" and “will” or similar expressions are intended to
identify forward-looking statements. Examples of these
forward-looking statements include statements concerning: Keros’
expectations regarding its growth, strategy, progress and the
design, objectives, results and timing of its clinical trials for
KER-012; and the potential of KER-012 to correct dysfunctional
activin signaling in PAH without a dose-limiting red blood cell
effect. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, among others: Keros’ limited
operating history and historical losses; Keros’ ability to raise
additional funding to complete the development and any
commercialization of its product candidates; Keros’ dependence on
the success of its product candidates, KER-050, KER-047 and
KER-012; that Keros may be delayed in initiating, enrolling or
completing any clinical trials; competition from third parties that
are developing products for similar uses; Keros’ ability to obtain,
maintain and protect its intellectual property; and Keros’
dependence on third parties in connection with manufacturing,
clinical trials and preclinical studies.
These and other risks are described more fully in Keros’ filings
with the Securities and Exchange Commission (“SEC”), including the
“Risk Factors” section of Keros’ Quarterly Report on Form 10-Q,
filed with the SEC on May 4, 2023, and its other documents
subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Keros undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Contact:
Justin Frantzjfrantz@kerostx.com617-221-6042
Keros Therapeutics (NASDAQ:KROS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Keros Therapeutics (NASDAQ:KROS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024